Biotech
A Drug Just Beat Keytruda on Survival for the First Time — by 8.2 Months
Ivonescimab lived a median 30.8 months vs Keytruda's 22.6 in a head-to-head lung cancer trial — the first clear survival win over the world's best-selling drug.
Topic
Immunotherapy
The latest Immunotherapy news and analysis from Tech Arcade.